Clinical Trial Update: Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravenous lidocaine for clinical outcomes in patients with acute respiratory distress syndrome (ARDS) and COVID-19 has been termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Lidocaine (intravenous) (lidocaine)

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Acute Respiratory Distress Syndrome (ARDS), COVID-19 | Phase 3 | Status: TERMINATED